These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8187318)

  • 21. Growth response and levels of growth factors after two years growth hormone treatment are similar for a once and twice daily injection regimen in girls with Turner syndrome. (Dutch Working Group on Growth Hormone).
    van Teunenbroek A; de Muinck Keizer-Schrama S; Stijnen T; Waelkens J; Wit JM; Vulsma T; Gerver WJ; Reeser H; Delemarre-van de Waal H; Jansen M; Drop S
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):451-9. PubMed ID: 9196608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 24-h profile of serum osteocalcin in growth hormone (GH) deficient patients with and without GH treatment.
    Nielsen HK; Jørgensen JO; Brixen K; Møller N; Charles P; Christensen JS
    Growth Regul; 1991 Dec; 1(4):153-9. PubMed ID: 1842347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The study of spontaneous GH secretion after 36-h fasting distinguishes between GH-deficient and normal adults.
    Aimaretti G; Colao A; Corneli G; Pivonello R; MacCario M; Morrison K; Pflaum CD; Strasburger CJ; Lombardi G; Ghigo E
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):771-7. PubMed ID: 10619983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole body and regional soft tissue changes in growth hormone deficient adults after one year of growth hormone treatment: a double-blind, randomized, placebo-controlled study.
    Hansen TB; Vahl N; Jørgensen JO; Christiansen JS; Hagen C
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):689-96. PubMed ID: 8736270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance.
    Bülow B; Erfurth EM
    Clin Endocrinol (Oxf); 1999 Jan; 50(1):45-55. PubMed ID: 10341855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition.
    Jørgensen JO; Vahl N; Hansen TB; Thuesen L; Hagen C; Christiansen JS
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):681-8. PubMed ID: 9039333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices.
    Jørgensen JO; Møller N; Lauritzen T; Christiansen JS
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1616-23. PubMed ID: 2189886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome).
    Cotterill AM; Camacho-Hübner C; Holly JM; Savage MO
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):119-22. PubMed ID: 7688671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
    Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL; Wallace WH; Shalet SM
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh.
    Beshyah SA; Anyaoku V; Niththyananthan R; Sharp P; Johnston DG
    Clin Endocrinol (Oxf); 1991 Nov; 35(5):409-12. PubMed ID: 1814654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters.
    Møller J; Jørgensen JO; Lauersen T; Frystyk J; Naeraa RW; Orskov H; Christiansen JS
    Clin Endocrinol (Oxf); 1993 Oct; 39(4):403-8. PubMed ID: 7507009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults.
    Jørgensen JO; Møller J; Laursen T; Orskov H; Christiansen JS; Weeke J
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):609-14. PubMed ID: 7828350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers didecanoyl-L-alpha-phosphatidylcholine and alpha-cyclodextrin in rabbits.
    Agerholm C; Bastholm L; Johansen PB; Nielsen MH; Elling F
    J Pharm Sci; 1994 Dec; 83(12):1706-11. PubMed ID: 7891298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.
    Hilding A; Brismar K; Degerblad M; Thorén M; Hall K
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2646-52. PubMed ID: 7545695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships.
    Vance ML; Evans WS; Kaiser DL; Burke RL; Rivier J; Vale W; Thorner MO
    Clin Pharmacol Ther; 1986 Dec; 40(6):627-33. PubMed ID: 3096623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults.
    Oscarsson J; Johannsson G; Johansson JO; Lundberg PA; Lindstedt G; Bengtsson BA
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):63-8. PubMed ID: 9059559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy.
    Rosenfalck AM; Fisker S; Hilsted J; Dinesen B; Vølund A; Jørgensen JO; Christiansen JS; Madsbad S
    Growth Horm IGF Res; 1999 Apr; 9(2):96-105. PubMed ID: 10373342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.
    Micic D; Popovic V; Kendereski A; Peino R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):543-51. PubMed ID: 8977750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.